Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0LATBR
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
IgG1-ADC-07
|
|||||
| Synonyms |
IgG1 ADC 07
Click to Show/Hide
|
|||||
| Organization |
Suzhou Medilink Therapeutics Ltd.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-Lysozyme mAb
|
Antibody Info | ||||
| Antigen Name |
Epidermal growth factor receptor (EGFR); Receptor tyrosine-protein kinase erbB-3 (ERBB3)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Linker Name |
IgG1-ADC-07 linker
|
|||||
General Information of The Activity Data Related to This ADC
Discovered Using Patient-derived Xenograft Model
Discovered Using Cell Line-derived Xenograft Model
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Patient-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 81.28% (Day 22) | |||
| Method Description |
Conjugates of the exemplary antibodies were tested using an established PDX model of esophageal squamous cell carcinoma cell implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 10 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
|
||||
| In Vivo Model | Esophageal squamous cell carcinoma PDX model (PDX: ES0204) | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 88.81% (Day 22) | |||
| Method Description |
Conjugates of the exemplary antibodies were tested using an established PDX model of prostate cancer cell implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 10 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
|
||||
| In Vivo Model | Prostate cancer PDX model (PDX: PR9586) | ||||
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 37.64% (Day 15) | |||
| Method Description |
Conjugates of the exemplary antibodies were tested using an established xenograft model of SW480 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 10 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
|
||||
| In Vivo Model | SW480 CDX model | ||||
| In Vitro Model | Colon adenocarcinoma | SW480 cells | CVCL_0546 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 49.17% (Day 29) | |||
| Method Description |
Conjugates of the exemplary antibodies were tested using an established xenograft model of NCI-H358 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 5 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
|
||||
| In Vivo Model | NCI-H358 CDX model | ||||
| In Vitro Model | Minimally invasive lung adenocarcinoma | NCI-H358 cells | CVCL_1559 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 53.80% (Day 18) | |||
| Method Description |
Conjugates of the exemplary antibodies were tested using an established xenograft model of SW480 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 10 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
|
||||
| In Vivo Model | SW480 CDX model | ||||
| In Vitro Model | Colon adenocarcinoma | SW480 cells | CVCL_0546 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.